These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32677805)

  • 1. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
    Yamauchi M; Ono A; Ishikawa A; Kodama K; Uchikawa S; Hatooka H; Zhang P; Teraoka Y; Morio K; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Hayes CN; Fujita M; Nakagawa H; Yasui W; Aikata H; Chayama K
    Clin Transl Gastroenterol; 2020 May; 11(5):e00179. PubMed ID: 32677805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
    Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
    Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
    Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
    Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
    Iseda N; Itoh S; Toshida K; Tomiyama T; Morinaga A; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Yoshizumi T; Mori M
    Cancer Sci; 2022 Jul; 113(7):2272-2287. PubMed ID: 35466502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.
    Azuma S; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Kondo M; Numata K; Iwabuchi S; Kako M; Maeda S; Koizumi W; Atsuda K
    Sci Rep; 2020 Oct; 10(1):17054. PubMed ID: 33051476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
    Lin PT; Teng W; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
    J Formos Med Assoc; 2024 Jul; 123(7):788-795. PubMed ID: 38310071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
    Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
    Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
    Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
    Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Lenvatinib in Combination With PD-1 Monoclonal Antibody and Interventional Treatment for Intermediate-Stage Hepatocellular Carcinoma: Impact on Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Levels: A Retrospective Study.
    Zhu J; Wu Y; Zhang H; Yang J; An Y; Shao S; Xia N
    Technol Cancer Res Treat; 2024; 23():15330338241256812. PubMed ID: 38802996
    [No Abstract]   [Full Text] [Related]  

  • 19. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.
    Zhu J; Fang P; Wang C; Gu M; Pan B; Guo W; Yang X; Wang B
    Cancer Med; 2021 Nov; 10(22):7977-7987. PubMed ID: 34605616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.